Exact Mass: 550.2679
Exact Mass Matches: 550.2679
Found 500 metabolites which its exact mass value is equals to given mass value 550.2679
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Desglucocheirotoxin
Convallatoxin is a cardenolide glycoside that consists of strophanthidin having a 6-deoxy-alpha-L-mannopyranosyl (L-rhamnosyl) group attached at position 3. It has a role as a vasodilator agent and a metabolite. It is an alpha-L-rhamnoside, a 19-oxo steroid, a 14beta-hydroxy steroid, a 5beta-hydroxy steroid, a steroid lactone and a steroid aldehyde. It is functionally related to a strophanthidin. Convallatoxin is a natural product found in Crossosoma bigelovii, Convallaria keiskei, and other organisms with data available. Convallatoxin is a glycoside extracted from Convallaria majalis. Convallatoxin is also isolated from the trunk bark of Antiaris toxicaria (A15340). Convallatoxin is a constituent of Convallaria majalis. Convallaria majalis has been designated unsafe for inclusion in foods etc. by USA FDA Constituent of Convallaria majalis. Convallaria majalis has been designated unsafe for inclusion in foods etc. by USA FDA. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties[1][2][3]. Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties[1][2][3].
Adonitoxin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
Manumycin A
A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. Manumycin A is a polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. It has a role as an EC 1.8.1.9 (thioredoxin reductase) inhibitor, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor, an antineoplastic agent, an apoptosis inducer, an antimicrobial agent, a bacterial metabolite, an antiatherosclerotic agent and a marine metabolite. It is a polyketide, an enamide, an epoxide, an organic heterobicyclic compound, a secondary carboxamide and a tertiary alcohol. Manumycin A is a natural product found in Streptomyces, Streptomyces griseoaurantiacus, and Streptomyces parvulus D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors
Manumycin A
Fantofarone
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
PA(2:0/PGF2alpha)
PA(2:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGF2alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF2alpha/2:0)
PA(PGF2alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/2:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGE1)
PA(2:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGE1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE1/2:0)
PA(PGE1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/2:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGD1)
PA(2:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGD1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD1/2:0)
PA(PGD1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/2:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
pseudolaric acid A O-beta-d-glucopyranoside
Pseudolaric acid A-O-β-D-glucopyranoside, isolated from Cortex Pseudolaricis, demonstrates antifungal and antifertility activities[1]. Pseudolaric acid A-O-β-D-glucopyranoside, isolated from Cortex Pseudolaricis, demonstrates antifungal and antifertility activities[1].
19-Aldehyde,3-O-beta-D-allomethyloside-(3beta,5alpha,14beta,17betaOH)-3,14,17,19-Tetrahydroxycard-20(22)-enolide
(1R*,2R*,3S*,5Z,7S*,8S*,9S*,10S*,11R*,12S*,14S*,17R*)-2,3,14-triacetoxy-8,9,11,12-bisepoxy-17-hydroxybriar-5-en-18-one
3beta,8beta-diangeloyloxy-5alpha,9beta-diacetoxy-4alpha-hydroxy-1beta,10alpha-epoxygermacr-11-ene
17-benzoyloxy-3-O-(2,3-dimethylbutanoyl)-20-deoxyingenol
michaolide J
A cembrane diterpenoid with cytotoxic activity isolated from the soft coral Lobophytum michaelae.
(1R,3aS,4Z,8S,8aR,9S,12aS,13S,13aR)-8,9,13-tris(acetyloxy)-5-[(acetyloxy)methyl]-3a,6,7,8,8a,9,10,11,12,12a,13,13a-dodecahydro-13a-hydroxy-1,8a-dimethyl-12-methylidenebenzo[4,5]cyclodeca[1,2-b]furan-2(1H)-one|junceellonoid B
(3S,5R,6S,7E,9S)-megastigman-7-ene-5,6-epoxy-3,9-diol
12alpha-ethoxyl-1alpha,6alpha,7beta-triacetoxy-5alpha,14beta-dihydroxy-cass-13(15)-en-16,12-olide
4-acetate-1,2,3,5-tetrakis(2-methyl-2-butenoate)inositol
antiaroside E
3-acetate-1,2,4,5-tetrakis(2-methyl-2-butenoate)inositol
7beta,9,10beta,20-tetracetoxy-13beta,17-epoxy-3,8-secotaxa-3E,8E,11-triene-2alpha,5alpha-diol|canataxpyran A
1-O-cinnamoyl-17-defurano-17-oxosalannicacid methyl ester|17-defurano-17-oxoohchinin
Convallatoxin
Convallatoxin is a cardenolide glycoside that consists of strophanthidin having a 6-deoxy-alpha-L-mannopyranosyl (L-rhamnosyl) group attached at position 3. It has a role as a vasodilator agent and a metabolite. It is an alpha-L-rhamnoside, a 19-oxo steroid, a 14beta-hydroxy steroid, a 5beta-hydroxy steroid, a steroid lactone and a steroid aldehyde. It is functionally related to a strophanthidin. Convallatoxin is a natural product found in Crossosoma bigelovii, Convallaria keiskei, and other organisms with data available. Convallatoxin is a glycoside extracted from Convallaria majalis. Convallatoxin is also isolated from the trunk bark of Antiaris toxicaria (A15340). A cardenolide glycoside that consists of strophanthidin having a 6-deoxy-alpha-L-mannopyranosyl (L-rhamnosyl) group attached at position 3. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties[1][2][3]. Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties[1][2][3].
3-O-angeloyl-17-(benzoyloxy)ingenol|ingenol-3-angelate-17-benzoate
3beta,-angeloyloxy-5alpha,9beta-diacetoxy-4alpha-hydroxy-8beta-senecioyloxy-1beta,10alpha-epoxygermacr-11-ene
corotoxigenin 3beta-D-glucoside|Cortoxigenin-3-beta-D-glucosid|glucocorotoxigenin
15-hydroxysolanascone-beta-glucopyranoside tetraacetate
(1R*,3aS*,4Z,8S*,8aS*,9S*,11R*,12aS*,13S*,13aS*)-1,2,3a,6,7,8,8a,9,10,11,12,12a,13,13a-tetradecahydro-13a-hydroxy-1,5,8a-trimethyl-12-methylidene-2-oxobenzo[4,5]cyclodeca[1,2-b]furan-8,9,11,13-tetrayl tetraacetate|frajunolide A|rel-(1S,2S,5Z,7S,8S,9S,10S,12R,14S,17R)-2,9,12,14-tetraacetoxy-8-hydroxybriara-5,11(20)-dien-18,7-olide
Gln Phe Glu Lys
Lys Gln Phe Glu
PseudolaricacidAbeta-D-glucoside
PseudolaricacidAbeta-D-glucoside is a natural product found in Pseudolarix amabilis and Larix kaempferi with data available. Pseudolaric acid A-O-β-D-glucopyranoside, isolated from Cortex Pseudolaricis, demonstrates antifungal and antifertility activities[1]. Pseudolaric acid A-O-β-D-glucopyranoside, isolated from Cortex Pseudolaricis, demonstrates antifungal and antifertility activities[1].
Ala Phe Lys Trp
Ala Phe Gln Trp
Ala Phe Trp Lys
Ala Phe Trp Gln
Ala Lys Phe Trp
Ala Lys Trp Phe
Ala Gln Phe Trp
Ala Gln Trp Phe
Ala Trp Phe Lys
Ala Trp Phe Gln
Ala Trp Lys Phe
Ala Trp Gln Phe
Asp Phe Asn Arg
Asp Phe Arg Asn
Asp Asn Phe Arg
Asp Asn Arg Phe
Asp Arg Phe Asn
Asp Arg Asn Phe
Glu Phe Lys Gln
Glu Phe Gln Lys
Glu Lys Phe Gln
Glu Lys Gln Phe
Glu Gln Phe Lys
Glu Gln Lys Phe
Phe Ala Lys Trp
Phe Ala Gln Trp
Phe Ala Trp Lys
Phe Ala Trp Gln
Phe Asp Asn Arg
Phe Asp Arg Asn
Phe Glu Lys Gln
Phe Glu Gln Lys
Phe Phe His Thr
Phe Phe Thr His
Phe His Phe Thr
Phe His Thr Phe
Phe Lys Ala Trp
Phe Lys Glu Gln
Phe Lys Gln Glu
Phe Lys Trp Ala
Phe Asn Asp Arg
Phe Asn Arg Asp
Phe Gln Ala Trp
Phe Gln Glu Lys
Phe Gln Lys Glu
Phe Gln Arg Thr
Phe Gln Thr Arg
Phe Gln Trp Ala
Phe Arg Asp Asn
Phe Arg Asn Asp
Phe Arg Gln Thr
Phe Arg Thr Gln
Phe Thr Phe His
Phe Thr His Phe
Phe Thr Gln Arg
Phe Thr Arg Gln
Phe Trp Ala Lys
Phe Trp Ala Gln
Phe Trp Lys Ala
Phe Trp Gln Ala
His Phe Phe Thr
His Phe Thr Phe
His Thr Phe Phe
Ile Gln Gln Tyr
Ile Gln Tyr Gln
Ile Tyr Gln Gln
Lys Ala Phe Trp
Lys Ala Trp Phe
Lys Glu Phe Gln
Lys Glu Gln Phe
Lys Phe Ala Trp
Lys Phe Glu Gln
Lys Phe Gln Glu
Lys Phe Trp Ala
Lys Met Ser Trp
Lys Met Trp Ser
Lys Gln Glu Phe
Lys Ser Met Trp
Lys Ser Trp Met
Lys Trp Ala Phe
Lys Trp Phe Ala
Lys Trp Met Ser
Lys Trp Ser Met
Leu Gln Gln Tyr
Leu Gln Tyr Gln
Leu Tyr Gln Gln
Met Lys Ser Trp
Met Lys Trp Ser
Met Ser Lys Trp
Met Ser Trp Lys
Met Trp Lys Ser
Met Trp Ser Lys
Asn Asp Phe Arg
Asn Asp Arg Phe
Asn Phe Asp Arg
Asn Phe Arg Asp
Asn Arg Asp Phe
Asn Arg Phe Asp
Asn Arg Val Tyr
Asn Arg Tyr Val
Asn Val Arg Tyr
Asn Val Tyr Arg
Asn Tyr Arg Val
Asn Tyr Val Arg
Gln Ala Phe Trp
Gln Ala Trp Phe
Gln Glu Phe Lys
Gln Glu Lys Phe
Gln Phe Ala Trp
Gln Phe Lys Glu
Gln Phe Arg Thr
Gln Phe Thr Arg
Gln Phe Trp Ala
Gln Ile Gln Tyr
Gln Ile Tyr Gln
Gln Lys Glu Phe
Gln Lys Phe Glu
Gln Leu Gln Tyr
Gln Leu Tyr Gln
Gln Gln Ile Tyr
Gln Gln Leu Tyr
Gln Gln Tyr Ile
Gln Gln Tyr Leu
Gln Arg Phe Thr
Gln Arg Thr Phe
Gln Thr Phe Arg
Gln Thr Arg Phe
Gln Trp Ala Phe
Gln Trp Phe Ala
Gln Tyr Ile Gln
Gln Tyr Leu Gln
Gln Tyr Gln Ile
Gln Tyr Gln Leu
Arg Asp Phe Asn
Arg Asp Asn Phe
Arg Phe Asp Asn
Arg Phe Asn Asp
Arg Phe Gln Thr
Arg Phe Thr Gln
Arg Asn Asp Phe
Arg Asn Phe Asp
Arg Asn Val Tyr
Arg Asn Tyr Val
Arg Gln Phe Thr
Arg Gln Thr Phe
Arg Thr Phe Gln
Arg Thr Gln Phe
Arg Val Asn Tyr
Arg Val Tyr Asn
Arg Tyr Asn Val
Arg Tyr Val Asn
Ser Lys Met Trp
Ser Lys Trp Met
Ser Met Lys Trp
Ser Met Trp Lys
Ser Trp Lys Met
Ser Trp Met Lys
Thr Phe Phe His
Thr Phe His Phe
Thr Phe Gln Arg
Thr Phe Arg Gln
Thr His Phe Phe
Thr Gln Phe Arg
Thr Gln Arg Phe
Thr Arg Phe Gln
Thr Arg Gln Phe
Val Asn Arg Tyr
Val Asn Tyr Arg
Val Arg Asn Tyr
Val Arg Tyr Asn
Val Tyr Asn Arg
Val Tyr Arg Asn
Trp Ala Phe Lys
Trp Ala Phe Gln
Trp Ala Lys Phe
Trp Ala Gln Phe
Trp Phe Ala Lys
Trp Phe Ala Gln
Trp Phe Lys Ala
Trp Phe Gln Ala
Trp Lys Ala Phe
Trp Lys Phe Ala
Trp Lys Met Ser
Trp Lys Ser Met
Trp Met Lys Ser
Trp Met Ser Lys
Trp Gln Ala Phe
Trp Gln Phe Ala
Trp Ser Lys Met
Trp Ser Met Lys
Tyr Ile Gln Gln
Tyr Leu Gln Gln
Tyr Asn Arg Val
Tyr Asn Val Arg
Tyr Gln Ile Gln
Tyr Gln Leu Gln
Tyr Gln Gln Ile
Tyr Gln Gln Leu
Tyr Arg Asn Val
Tyr Arg Val Asn
Tyr Val Asn Arg
Tyr Val Arg Asn
Antiaroside C
benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid
R-3,3-Bis(4-(1,1-dimethylethyl)phenyl)-1,1-bi-2-naphthol
(S)-4-(2-amino-3-((2-aminoethyl)amino)propyl)phenol hydrochloride
Manumycin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors
Ajugapitin
A diterpenoid isolated from the aerial parts of Ajuga bracteosa and has been shown to exhibit antifeedant activity against Spodoptera littoralis.
methyl (1beta,11beta,12alpha,15beta)-15-{[(2E)-3,4-dimethylpent-2-enoyl]oxy}-1,11,12-trihydroxy-2,16-dioxo-13,20-epoxypicrasan-21-oate
(R)-2,4,6-Trimethyl-deca-2,4-dienoic acid {(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-6-(2-hydroxy-5-oxo-cyclopent-1-enylcarbamoyl)-hexa-1,3,5-trienyl]-2-oxo-7-oxa-bicyclo[4.1.0]hept-3-en-3-yl}-amide
2-methoxy-N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[(5-phenyl-3-isoxazolyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
(2E,4E,6R)-N-[(5S,6R)-5-[(1E,3E,5E)-7-[(2,5-dioxocyclopentyl)amino]-7-oxohepta-1,3,5-trienyl]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
2-[(2S,3R,4S,5R)-5-[[4-[[benzyl(methyl)amino]methyl]triazol-1-yl]methyl]-3,4-dihydroxyoxolan-2-yl]-1-[4-(2-methoxyphenyl)piperazin-1-yl]ethanone
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
Desglucocheirotoxin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins
1-(9Z-octadecenoyl)-2-glutaryl-sn-glycero-3-phosphate
bruceanol E
A quassinoid that is the dihydro derivative of bruceanol D. Isolated from Brucea antidysenterica, it exhibits in vitro cytotoxicity towards several human tumour cell lines.
(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5-[(2s)-2-hydroxy-2-(5-oxo-2h-furan-3-yl)ethyl]-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl (2r)-2-methylbutanoate
(9ar,11as)-1-{2-hydroxy-1-[5-(methoxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl}-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthrene-7-sulfonic acid
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 5-[7-(acetyloxy)-4,9-dimethyl-11-oxo-10-oxatricyclo[6.3.2.0¹,⁷]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
5'-(acetyloxy)-6'a-[(acetyloxy)methyl]-4'a,10'b-dimethyl-5''-oxo-octahydrodispiro[oxirane-2,7'-naphtho[2,1-b]pyran-3',3''-oxolan]-6'-yl 2-methylbutanoate
methyl (2s,3r,5r)-2-{[(1r,3as,3br,5as,7r,8r,9ar,9bs,11ar)-3a,8,9a-trihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-5-methyloxolane-3-carboxylate
(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
2,10,14-tris(acetyloxy)-3-hydroxy-4,9,13-trimethyl-17-methylidene-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadec-8-en-12-yl acetate
[(1s,2s,3s,4r,7s,8e,12s,13s,14r)-2,12,14-tris(acetyloxy)-3-hydroxy-4,13,17-trimethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,16-dien-9-yl]methyl acetate
5a,10-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde
(9r,13s,16s,17r,18s)-16-[(1r)-1-hydroxy-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate
n-[(1ar,2s,6as,6bs)-5-{1-[(1ar,2s,6as,6bs)-4-[(1-hydroxy-3-methylbut-2-en-1-ylidene)amino]-2,6a-dimethyl-6-oxo-1ah,2h,6bh-oxireno[2,3-a]pyrrolizin-5-yl]ethyl}-2,6a-dimethyl-6-oxo-1ah,2h,6bh-oxireno[2,3-a]pyrrolizin-4-yl]-3-methylbut-2-enimidic acid
4-(3-{3a,5a,7,8,11-pentahydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-3-hydroxy-2-oxobutyl)-3,5-dimethyloxolan-2-one
(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid
3a-hydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthrene-9a-carbaldehyde
(1r,2s,5r,6r,13s,14r,16s)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadeca-9,11-dien-14-yl (2z)-2-methylbut-2-enoate
methyl (3as,4s,5s,11ar)-4-{[(2s,3r)-3-(acetyloxy)-2-hydroxy-2-methylbutanoyl]oxy}-10-methyl-5-{[(2s)-2-methylbutanoyl]oxy}-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-carboxylate
9α,10β-diacetoxy-5α-cinnamoyloxytaxa-4(20),11-dien-13α-ol
{"Ingredient_id": "HBIN014037","Ingredient_name": "9\u03b1,10\u03b2-diacetoxy-5\u03b1-cinnamoyloxytaxa-4(20),11-dien-13\u03b1-ol","Alias": "NA","Ingredient_formula": "C33H42O7","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5288","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}